Telehealth Weight Loss/GLP-1 Prescribing: What Psychiatric NPs Can Do

If you’re a psychiatrist or PMHNP watching the GLP-1 revolution unfold, you’ve probably asked yourself: ‘Can I prescribe these medications? Should I?’ The short answer: Yes, in most cases—but the details matter. Your scope of practice, state regulations, and telehealth rules create a patchwork of requirements that can either open doors or create compliance headaches.

Here’s what you need to know about prescribing weight-loss medications as a psychiatric provider in 2026, including the business case, regulatory landscape, and how platforms like Klarity Health handle the complexity for you.

Why Psychiatrists Are Entering Weight Management (And Why It Makes Sense)

Let’s address the elephant in the room: ‘Isn’t weight loss outside my scope?’

Not necessarily. Many of your patients already struggle with medication-induced weight gain from antipsychotics, mood stabilizers, or antidepressants. Obesity itself exacerbates depression, anxiety, and metabolic syndrome. If you’re already monitoring lipids and glucose for patients on psychiatric meds, you’re already practicing metabolic-psychiatric care—whether you call it that or not.

The emergence of GLP-1 medications (semaglutide/Wegovy, tirzepatide, liraglutide) has blurred traditional specialty boundaries. These drugs don’t just aid weight loss—they’re showing ancillary benefits for mental health: reduced cravings in substance use disorders, improved mood scores independent of weight loss, and potential anti-inflammatory effects on the brain.

The competency argument: Scope of practice isn’t defined by your specialty title—it’s defined by your training and competence. If a psychiatrist gains the requisite knowledge in obesity medicine (through CME, mentorship, or even board certification in obesity medicine—yes, psychiatrists are eligible), prescribing GLP-1s becomes a reasonable extension of comprehensive care.

As Dr. Elliott Lewis, a dual-boarded psychiatrist and obesity medicine specialist, puts it: ‘If we truly understand that metabolic and mental health systems are inseparable, then psychiatrists being involved in metabolic treatment makes complete sense.’

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

The Scope-of-Practice Reality: MDs vs. PMHNPs

Psychiatrists (MD/DO): Broad Authority, But State Rules Still Apply

As a licensed physician, you have full prescriptive authority in all 50 states. You can prescribe FDA-approved weight-loss medications—GLP-1 agonists, phentermine (Schedule IV), orlistat, etc.—without additional certification.

However: Individual state medical boards impose specific standards for weight-loss prescribing. For example:

• Florida requires documented BMI ≥30 (or ≥27 with comorbidity), a comprehensive physical exam (which can be delegated to an APRN/PA), written informed consent, and face-to-face follow-ups every 3 months.
• New Jersey mandates a thorough workup including assessment for psychiatric conditions before initiating weight-loss meds, plus documented nutritional counseling and exercise recommendations.
• Virginia requires monthly follow-ups for the first few months of treatment.
• Mississippi has banned off-label prescribing of GLP-1 agonists solely for weight loss—you must use FDA-approved obesity formulations (like Wegovy, not Ozempic for non-diabetics).

Bottom line: You have the authority, but you must follow your state’s clinical guidelines. Cutting corners (like skipping the 3-month follow-up in Florida or prescribing to someone with BMI 24) can trigger board investigations.

PMHNPs: State-by-State Variability

If you’re a psychiatric nurse practitioner, your prescribing authority depends entirely on where you practice:

Full Practice Authority (FPA) States (~26 states + D.C.):
In states like Illinois, New York (after 3,600 hours), Washington, and New Mexico, experienced NPs can prescribe weight-loss medications independently—including controlled substances like phentermine—without physician oversight. In Illinois, for example, NPs with FPA can prescribe Schedule II–V medications after meeting training requirements.

Reduced/Restricted Practice States (the rest):
States like Texas, Florida, Pennsylvania, and California require written collaborative agreements or protocols with a supervising physician. Specifics:

• Texas: All NPs must have a Prescriptive Authority Agreement with a Texas-licensed MD. The agreement must detail scope, communication plans, and chart reviews. One physician can supervise up to 7 NP/PA prescribers.
• Florida: PMHNPs must have a protocol with a supervising physician. Florida’s ‘Autonomous APRN’ registration excludes psychiatric NPs and doesn’t permit independent prescribing of controlled substances. You’ll always need MD collaboration.
• Pennsylvania: CRNPs need a collaborative agreement; prescription blanks must include both the NP’s name and the collaborating physician’s name.
• California: NPs currently need physician-approved ‘standardized procedures’ to prescribe. AB 890 is phasing in independence—by January 2026, qualified ‘104’ NPs can practice independently—but California’s Corporate Practice of Medicine doctrine still requires physician involvement in clinic ownership and oversight.

The PMHNP Specialty Question:
Even in FPA states, there’s a gray area: does a psychiatric NP’s scope include weight management? Nurse practitioners are trained in population-specific care. A PMHNP’s formal training emphasizes mental health, not metabolic disorders. However, scope isn’t rigidly compartmentalized. If you’re managing a patient with antipsychotic-induced weight gain, prescribing metformin or a GLP-1 to mitigate metabolic side effects is arguably within holistic psychiatric care.

That said, if you’re advertising a standalone weight-loss clinic as a PMHNP, state boards might scrutinize whether you have adequate training. Many psychiatric NPs pursuing this pathway obtain supplemental obesity medicine education or work under an MD protocol that explicitly covers weight management.

Practical Barriers Even in FPA States:
Even where legally independent, NPs often face real-world friction. Insurers and pharmacies sometimes require physician sign-off for high-cost GLP-1 prescriptions, even if state law doesn’t mandate it. Prior authorizations may ask for an MD’s name. This is why many telehealth platforms (including Klarity) maintain physician medical directors in every state—to smooth credentialing, provide clinical oversight, and remove barriers for both NPs and patients.

Telehealth Prescribing: Federal Green Light, State Red Lights

Telehealth has opened weight management to millions, but navigating the rules requires vigilance.

Federal Waivers: Extended Through 2025

The DEA’s COVID-era waivers allowing controlled substance prescribing via telehealth (without an initial in-person exam) have been extended through December 31, 2025. This means you can legally prescribe phentermine (Schedule IV) or other controlled weight-loss medications remotely at the federal level.

State Laws Can Override Federal Rules

Here’s the trap: State law takes precedence. Even with federal permission, some states explicitly prohibit or heavily restrict telehealth prescribing of controlled substances:

Florida: State law bans telehealth prescriptions of controlled substances except for psychiatric treatment, inpatient/hospice care, or emergency addiction treatment. Weight loss isn’t listed. This means you cannot prescribe phentermine via telehealth to a Florida patient under current state law—even though the DEA allows it federally. (GLP-1s like semaglutide are not controlled and are allowed via telehealth in FL, as long as you meet the state’s obesity treatment standards.)

Alabama: Requires an initial in-person exam to prescribe any controlled substance. Telehealth-only controlled prescribing is prohibited.

Texas, New York, Pennsylvania, Illinois, California: Generally align with federal telehealth flexibilities. No state-imposed ban on controlled substance prescribing via telehealth (as long as standard of care is met). However, each has nuances:

• Texas requires PMP checks and proper documentation of the telehealth encounter.
• New York requires consultation of the state Prescription Monitoring Program (I-STOP) before prescribing Schedule II–IV drugs.
• Pennsylvania and Illinois follow federal rules; Illinois requires prescribers to use the state PMP and register for it.

Non-Controlled GLP-1s: Easier, But Not Without Rules

Since GLP-1 agonists (semaglutide, tirzepatide) are not controlled substances, they’re generally allowed via telehealth in all states. However, you still must:

• Establish a valid provider-patient relationship (usually via video consult for initial visit).
• Meet state-specific obesity treatment standards (BMI documentation, informed consent, follow-up schedules).
• Ensure any compounded semaglutide is from an FDA-registered facility (some states like Alabama have explicitly warned against non-compliant compounding).

Best Practice:
Use live video for the initial consultation. Document weight, BMI, relevant labs (TSH, A1C, lipids), and any comorbidities. Some telehealth platforms partner with local labs or use patient-reported metrics with photo documentation to approximate in-person exam elements.

Reimbursement: Is Weight Management Financially Viable?

Short answer: Yes, and it’s getting better.

Insurance Coverage for GLP-1 Medications

Until recently, weight-loss drugs had limited insurance coverage. That’s changing fast:

• Commercial Insurers: Most major payers now cover FDA-approved GLP-1s (Wegovy, Saxenda) with prior authorization. Typical PA requirements: BMI ≥30 (or ≥27 with comorbidity), documentation of lifestyle interventions, and often a requirement that the prescriber coordinates diet/exercise counseling.
• Medicare: As of late 2025, Medicare announced it will begin covering anti-obesity medications like Wegovy and Mounjaro—a monumental shift that opens treatment to millions of seniors. Full implementation expected in 2026.
• Medicaid: Coverage varies by state, but many are expanding access following the Medicare lead.

Quantity Limits: Some insurers (like certain Blue Cross plans) impose 30-day supply limits initially to monitor adherence and tolerance before approving refills.

Billing for Visits

Psychiatrists and PMHNPs typically use standard E/M codes or psychiatric evaluation codes for weight management visits:

• Initial Evaluation: CPT 90792 (psychiatric diagnostic evaluation) or 99203–99205 (new patient E/M) depending on complexity. Reimbursement ranges ~$150–$250.
• Follow-Ups: 99213–99214 (established patient E/M) or medication management codes. Expect $75–$150 per 15–30 minute visit.
• Obesity Counseling: CMS G0447 (15 minutes of face-to-face behavioral counseling for obesity) can be used if appropriate, though psychiatric providers more often use time-based E/M coding.

Telehealth Parity: Many states (California, New York, Illinois, Pennsylvania) have laws requiring insurers to reimburse telehealth visits at the same rate as in-person. Medicare continues reimbursing telehealth at office rates through at least 2025.

MDs vs. NPs:
Psychiatrists get 100% of physician fee schedules. PMHNPs typically receive 85% from Medicare (some private payers reimburse at 85–100%). Notably, Illinois Medicaid reimburses APRNs at 100% of physician rates, making NPs cost-competitive in that state.

The Economics

If you’re seeing patients for 20-minute medication management visits (weight loss + psychiatric follow-up), you can bill appropriately complex E/M codes. Combine that with insured patients whose GLP-1s are covered, and you have a sustainable service line—especially via telehealth where you can see higher volume without geographic constraints.

State-Specific Highlights: What You Need to Know

California

• NP Scope: Transitioning to independence via AB 890; full FPA by Jan 2026 for qualified NPs. However, Corporate Practice of Medicine still requires physician oversight of clinics.
• Prescribing: Psychiatrists have full authority. NPs can prescribe under protocols now; will gain independence for non-controlled drugs in 2026.
• Telehealth: Very permissive; parity law ensures equal reimbursement.

Texas

• NP Scope: Strict collaboration required. All NPs must have Prescriptive Authority Agreements with Texas MDs.
• Prescribing: Phentermine allowed (Schedule II amphetamines for weight loss are prohibited). PMP checks mandatory.
• Telehealth: Allowed; no state ban on controlled substance prescribing via telehealth (federal waivers apply). Must document proper evaluation.

Florida

• NP Scope: PMHNPs require physician protocols (no autonomous practice for psych NPs).
• Prescribing: Strict obesity treatment rules: BMI criteria, informed consent, 3-month follow-ups, PMP checks. Cannot prescribe controlled substances (like phentermine) via telehealth under state law. GLP-1s (non-controlled) are allowed via telehealth.
• Clinic Requirements: Weight-loss clinics must have a Florida-licensed MD medical director.

New York

• NP Scope: Reduced practice; NPs need collaboration initially, but can practice independently after 3,600 hours.
• Prescribing: No special obesity rules beyond standard care. PMP (I-STOP) check required for controlled substances.
• Telehealth: Strong parity laws; no state restrictions on controlled prescribing via telehealth beyond federal rules.

Pennsylvania

• NP Scope: Collaborative agreements required; no FPA yet.
• Prescribing: No state-specific obesity regulations. Collaboration agreement must authorize weight-loss prescribing.
• Telehealth: Generally permissive; no controlled substance ban.

Illinois

• NP Scope: Partial FPA state. Experienced NPs (≥4,000 hours + 250 hours CE) can gain full practice authority.
• Prescribing: No special obesity rules. APRNs with FPA can prescribe controlled substances independently (with some consultation requirements for Schedule II).
• Reimbursement: Medicaid reimburses APRNs at 100% of physician rates—major financial incentive.
• Telehealth: Strong parity; no state restrictions.

How to Get Started: Training, Competency, and Platforms

Training and Certification

If you’re serious about adding weight management to your practice, consider:

• CME in Obesity Medicine: Many accredited programs offer 20–60 hour courses.
• American Board of Obesity Medicine (ABOM) Certification: Open to physicians of any specialty (including psychiatry). Requires ~60 hours of obesity-related CME and passing a comprehensive exam. This credential directly addresses scope concerns and demonstrates formal proficiency.
• Collaborative Learning: Work alongside an obesity medicine specialist or endocrinologist initially to build competence.

Documentation Best Practices

To avoid regulatory issues:

• Document BMI and indications clearly. Most states and insurers require BMI ≥30 (or ≥27 with comorbidity).
• Obtain informed consent. Discuss risks, benefits, and alternatives. Some states (like Florida) require written consent.
• Schedule regular follow-ups. Adhere to state-mandated intervals (e.g., every 3 months in Florida).
• Check Prescription Monitoring Programs (PMPs) before prescribing controlled substances. Document the check in the patient’s chart.
• Coordinate care. Communicate with the patient’s PCP. Order necessary labs (TSH, glucose, lipids) to rule out secondary causes of obesity.

Joining a Telehealth Platform: The Klarity Advantage

Here’s where the rubber meets the road. Building a weight management practice from scratch—marketing, patient acquisition, credentialing, compliance—is expensive and time-consuming.

The DIY Marketing Reality:
Acquiring a qualified psychiatric patient through DIY marketing (SEO, Google Ads, directory listings) typically costs $200–500+ when you factor in:

• Agency/consultant fees
• Ad spend testing and optimization
• Staff time to handle and qualify leads
• No-show rates from cold leads
• 6–12 months of SEO investment before meaningful results
• Failed campaigns and wasted spend

Google Ads for mental health keywords run $15–40+ per click, and most clicks don’t convert to booked patients. SEO takes patience most solo providers don’t have. Directory listings (Psychology Today, Zocdoc) charge monthly fees AND you compete with hundreds of other providers.

Klarity’s Model:
Instead of gambling on marketing channels, Klarity uses a pay-per-appointment model:

• No upfront marketing spend or monthly subscription fees.
• Pre-qualified patients already matched to your specialty and availability.
• No wasted ad spend on clicks that don’t convert.
• Built-in telehealth infrastructure (no separate platform costs).
• Both insurance and cash-pay patient flow.
• You control your schedule—only pay when you see patients.

The Value Proposition:
Rather than spending $3,000–5,000/month on marketing with uncertain results, you pay a standard listing fee per new patient lead only when a qualified patient books with you. That’s guaranteed ROI vs. gambling on marketing channels.

For weight management specifically, Klarity handles:

• State-specific compliance: Ensuring protocols meet Florida’s 3-month follow-up rule, Texas’s collaboration requirements, etc.
• Prior authorizations: Support staff who know insurer requirements for GLP-1 coverage.
• Credentialing: Physician medical directors in every state to smooth insurance credentialing and provide oversight where needed (even in FPA states, to remove pharmacy/insurer barriers).
• Patient matching: Connecting you with patients who genuinely need psychiatric + metabolic care, not just cosmetic weight loss.

For PMHNPs:
If you’re in a restricted practice state (Texas, Florida, PA), Klarity provides access to collaborating physicians who understand psychiatric-metabolic care. No need to recruit and manage your own MD oversight.

For Psychiatrists:
Leverage your full prescriptive authority across all states where you’re licensed. Klarity’s infrastructure lets you focus on clinical care, not compliance paperwork or marketing funnels.

FAQs

Q: Can a psychiatrist prescribe Wegovy or Ozempic for weight loss?
A: Yes. Psychiatrists (MD/DO) have full authority to prescribe FDA-approved weight-loss medications in all states, provided they meet state-specific clinical standards (BMI criteria, informed consent, follow-ups, etc.). For off-label use (like Ozempic for non-diabetics), check your state—Mississippi explicitly bans this; most others allow it with proper documentation.

Q: Do PMHNPs need a collaborating physician to prescribe GLP-1s?
A: It depends on your state. In full practice authority states (like Illinois, New York after 3,600 hours, Washington), experienced NPs can prescribe independently. In states like Texas, Florida, and Pennsylvania, you need a written collaborative agreement with a physician that authorizes weight-loss prescribing. Even in FPA states, many NPs work with physician collaborators to ease insurance/pharmacy hurdles.

Q: Can I prescribe phentermine via telehealth?
A: Federally, yes (through Dec 31, 2025). However, state law matters more. Florida prohibits telehealth prescribing of controlled substances for weight loss. States like Texas, New York, Pennsylvania, Illinois, and California allow it if you meet standard-of-care requirements (proper evaluation, PMP check, documentation). Always verify your state’s rules.

Q: Is obesity treatment within a PMHNP’s scope of practice?
A: It can be, especially if tied to psychiatric care (e.g., managing medication-induced weight gain). Scope is defined by competency, not specialty title alone. If you pursue additional training in obesity medicine and work within a collaborative framework (where required), it’s defensible. However, advertising a standalone weight-loss clinic without relevant training might raise board scrutiny. Consider supplemental education or ABOM certification.

Q: What are the financial incentives for adding weight management?
A: Expanding insurance coverage (Medicare now covering GLP-1s in 2026), strong reimbursement for E/M visits ($75–$250 depending on complexity), and patient demand create a viable service line. Platforms like Klarity eliminate upfront marketing costs, so you only pay when you see patients—removing financial risk while adding revenue potential.

Q: What’s the biggest compliance risk?
A: Prescribing without meeting state-specific standards. Examples: skipping the mandatory 3-month follow-up in Florida, prescribing to a patient with BMI <30 without documented comorbidity, failing to check the PMP before writing phentermine, or using compounded semaglutide from non-FDA-registered facilities. These violations can trigger board investigations, fines, or license discipline.

Q: How do I verify a patient’s BMI for telehealth visits?
A: Most telehealth platforms use patient-reported height/weight with photo documentation or integration with wearable devices. Some partner with local labs for in-person vitals. For initial visits, require patients to submit recent measurements or visit a local clinic/pharmacy for a baseline weight and blood pressure reading. Document everything clearly.

The Bottom Line: An Opportunity for Forward-Thinking Providers

The intersection of psychiatric and metabolic health is no longer theoretical—it’s clinical reality. GLP-1 medications are proving effective not just for weight loss, but for improving quality of life in patients who struggle with obesity and mental health comorbidities.

For psychiatrists:
You already manage the metabolic fallout of psychiatric medications. Adding weight management (with proper training) is a logical extension of comprehensive care. You have the authority, the patient trust, and the clinical context. What you may lack is the infrastructure—and that’s where platforms like Klarity shine.

For PMHNPs:
Your path depends on your state. In FPA states, you can expand your scope with additional training. In collaborative states, you need the right MD partner—which Klarity provides. Either way, the demand is real and growing.

The economic case is clear:
Rather than spending thousands on marketing with no guarantee, join a platform that delivers pre-qualified patients and handles compliance, credentialing, and infrastructure. You focus on what you do best—helping patients—and get paid when they show up.

Ready to explore adding weight management to your practice?
Join Klarity Health’s provider network to connect with patients who need psychiatric and metabolic care, with full support for state compliance, credentialing, and patient matching. No upfront marketing spend. No compliance headaches. Just patients who need your expertise.

Citations and Sources

1. MedicalDirector Co. – ‘How Much Does a Collaborative Physician Cost for Weight Loss, Telehealth, and Medspas? (2025 Definitive Guide)’ (2025) www.medicaldirectorco.com

2. MedicalDirector Co. – ‘Florida Weight Loss Clinic and Telehealth Compliance Guide (2025)’ (Updated 2025) www.medicaldirectorco.com

3. MedicalDirector Co. – ‘Texas Weight Loss Clinic & Telehealth Compliance Guide (2025)’ (Updated 2025) www.medicaldirectorco.com

4. Florida Administrative Code R. 64B15-14.004 – ‘Standards for Prescription of Obesity Drugs’ (Effective Aug 8, 2022) www.law.cornell.edu

5. Foley & Lardner LLP via Mondaq – ‘A Changing Regulatory and Reimbursement Landscape for Weight-Loss Drugs’ (July 24, 2023) www.mondaq.com

Disclaimer: This content is for informational purposes only and does not constitute legal or medical advice. State laws and regulations change frequently. Providers should verify current requirements with their state medical/nursing boards and consult compliance counsel before implementing new services.

Source:

• https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/#:~:text=The%20answer%20is%20almost%20always,yes
• https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/#:~:text=Nurse%20Practitioners%20
• https://journals.lww.com/tnpj/fulltext/2024/01000/36thannualaprnlegislativeupdate__improving.6.aspx#:~:text=The%20Pennsylvania%20BON%20grants%20CRNPs%2C,more%20physicians%20to%20deliver%20healthcare
• https://journals.lww.com/tnpj/fulltext/2024/01000/36thannualaprnlegislativeupdate__improving.6.aspx#:~:text=The%20Illinois%20Department%20of%20Financial,collaborative%20agreement%20following%20a%20TTP
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20DEA%20gave%20us%20the,evaluation%20at%20the%20federal%20level
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=Despite%20federal%20DEA%20waivers%20extending,traps%20for%20digital%20health%20providers
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=1.%20Florida%3A%20The%20%22No,for%20Stimulants
• https://www.mondaq.com/unitedstates/healthcare/1447512/a-changing-regulatory-and-reimbursement-landscape-for-weight-loss-drugs#:~:text=New%20Jersey%20law%20requires%20that,and%20identify%20the%20risks%20associated
• https://drlewis.com/glp-1-medications-psychiatry/#:~:text=You%20know%20these%20drugs,disorders%2C%20and%20possibly%20depression%20itself
• https://drlewis.com/glp-1-mental-health/#:~:text=Now%20let%E2%80%99s%20talk%20about%20potential,where%20things%20get%20really%20interesting